TELL ME MORE ABOUT THIS STUDY
A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early investigational initiation as add-on treatment in COPD patients with type 2 inflammation
Enrolling Adults 40-75 Years
Study Location: Bowling Green, KY
Chronic obstructive pulmonary disease, or COPD, refers to a group of diseases that cause airflow blockage and breathing-related problems. COPD makes breathing difficult for the 16 million Americans who have this disease. Although there is no cure for COPD, it can be treated. (Source: CDC)
In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk. The presence of type 2 (T2) inflammation is a well-recognized feature of asthma; however, it is now apparent that a subset of COPD patients also displays evidence of T2 inflammation. (Source: NIH National Library of Medicine)
This study is for adults 40-75 years old with moderate to severe COPD with a history of at least 1 year of documented history of COPD , an elevated risk for exacerbations, and be a current or former cigarette smoker. This study will evaluate the efficacy and safety of an investigational medicine early therapy in COPD patients with Type 2 inflammation.
There is no cost to participate. Volunteers receive no cost investigational medicine and no cost health exams. No insurance needed. Reimbursement for time and travel is TBD.